![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Moderna Begins Dosing With COVID-19 Variant Booster Shot
Moderna Begins Dosing With COVID-19 Variant Booster Shot
March 15, 2021
Moderna has begun dosing trial participants with a modified COVID-19 vaccine meant to target the variant SARS-Cov-2 strain first identified in South Africa.
The new dosing will occur as part of an ongoing phase 2 study, the Cambridge, Mass., drugmaker said, with the trial enrolling 60 participants who previously received a shot of Moderna’s standard messenger RNA-based COVID-19 vaccine.
Moderna said participants will receive either a booster targeted at the South African variant or the company’s new multivalent vaccine candidate that targets both the original coronavirus strain and the variant strain.
Upcoming Events
-
21Oct